Novo Nordisk A/S buy Vip1959
Summary
This prediction ended on 22.05.17 with a price of €37.12. The BUY prediction by Vip1959 finished with a performance of 20.82%. Vip1959 has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Novo Nordisk A/S | - | - | - | - |
iShares Core DAX® | -2.926% | -4.228% | 9.878% | 12.466% |
iShares Nasdaq 100 | 4.462% | 8.605% | 33.063% | 59.465% |
iShares Nikkei 225® | 0.306% | 0.284% | 3.871% | 4.557% |
iShares S&P 500 | 2.488% | 4.773% | 27.189% | 50.113% |
Comments by Vip1959 for this prediction
In the thread Novo Nordisk A/S diskutieren
Vip1959 stimmt der Buy-Einschätzung von maskulin zu
Vip1959 stimmt am 07.02.2017 der Buy-Einschätzung von maskulin mit dem Kursziel 45€ zu.Überschrift: Ausblick enttäuschte...